SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells

References

• Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol, 2003;21:291–7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998;352:1413–18
   PubMed Web of Science ®Google Scholar
• Duan K, Zhang X, Tang X, Yu J, Liu S, Wang D, Li Y, Huang J. Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloids Surf B: Biointerfaces, 2010;76:475–82
   PubMed Web of Science ®Google Scholar
• Ebrahimnejad P, Dinarvand R, Jafari MR, Tabasi SAS, Atyabi F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int J Pharm, 2011;406:122–7
   PubMed Web of Science ®Google Scholar
• Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles. Eur J Pharm Biopharm, 2010;75:96–106
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res, 2002;8:641–61
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller RH. `Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces, 2000;18:301–13
   PubMed Web of Science ®Google Scholar
• Gu QR, Xing JZ, Huang M, He C, Chen J. SN-38 loaded polymeric micelles to enhance cancer therapy. Nanotechnology, 2012;23:205101
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)−poly(ethylene glycol)−folate conjugate. Langmuir, 2005;21:8852–7
   PubMed Web of Science ®Google Scholar
• Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S-I, Hamaguchi T, Matsumura Y. Novel SN-38–incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor–secreting bulky tumors. Cancer Res, 2006;66:10048–56
   PubMed Web of Science ®Google Scholar
• Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm Res, 2008;25:1723–9
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces, 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc, 2008;130:10876–7
   PubMed Web of Science ®Google Scholar
• Magenheim B, Levy MY, Benita S. A new in-vitro technique for the evaluation of drug-release profile from colloidal carriers – Ultrafiltration technique at low-pressure. Int J Pharm, 1993;94:115–23
   Web of Science ®Google Scholar
• Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol, 2011;9:55
   PubMed Web of Science ®Google Scholar
• Manaspon C, Hongeng S, Boongird A, Nasongkla N. Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system. J Pharm Sci, 2012;101:3708–17
   PubMed Web of Science ®Google Scholar
• Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev, 2011;63:184–92
   PubMed Web of Science ®Google Scholar
• Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, de Coupade C, Boukaissi M, Chéné A-S, Tranchant I, et al. DTS-108, a novel peptidic prodrug of SN38: In vivo efficacy and toxicokinetic studies. Clin Cancer Res, 2008;14:2145–53
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release, 2007;119:77–85
   PubMed Web of Science ®Google Scholar
• Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm, 1999;187:143–52
   PubMed Web of Science ®Google Scholar
• Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release, 1993;25:89–98
   Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl J Med, 2002;346:85–91
   PubMed Web of Science ®Google Scholar
• Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release, 2003;92:173–87
   PubMed Web of Science ®Google Scholar
• Patnaik A, Goldston M, Takimoto C, Tolcher A, Papadopoulos K, Bekaii-Saab T, Kleiber B, Gamza F, Longley C, Buchbinder A. 427 POSTER pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I dose-escalation study. Eur J Cancer Suppl, 2008;6:134
   Web of Science ®Google Scholar
• Peracchia MT, Gref R, Minamitake Y, Domb A, Lotan N, Langer R. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics. J Control Release, 1997;46:223–31
   Web of Science ®Google Scholar
• Sadzuka Y, Takabe H, Sonobe T. Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release, 2005;108:453–9
   PubMed Web of Science ®Google Scholar
• Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak ID. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11–refractory model. Clin Cancer Res, 2008;14:1888–96
   PubMed Web of Science ®Google Scholar
• Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitroassessment of potential drug interactions. Drug Metab Dispos, 1997;25:1157–64
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 2001;70:1–20
   PubMed Web of Science ®Google Scholar
• Tallman MN, Ritter JK, Smith PC. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (Sn-38) lactone and carboxylate in human and rat microsomes and recombinant udp-glucuronosyltransferase isoforms. Drug Metab Dispos, 2005;33:977–83
   PubMed Web of Science ®Google Scholar
• Thakur R, Sivakumar B, Savva M. Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions. J Phys Chem B, 2020;114:5903–11
   Web of Science ®Google Scholar
• Tobin P, Clarke S, Seale JP, Lee S, Solomon M, Aulds S, Crawford M, Gallagher J, Eyers T, Rivory L. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and β-glucuronidase in human colorectal tumours. Br J Clin Pharmacol, 2006;62:122–9
   PubMed Web of Science ®Google Scholar
• Wang H, Shrestha TB, Basel MT, Dani RK, Seo G-M, Balivada S, Pyle MM, Prock H, Koper OB, Thapa PS, et al. Magnetic-Fe/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages. Beilstein J Nanotechnol, 2012;3:444–55
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo M, Lu Y, Ding L-Y, Ron W-T, Liu Y-Q, Song F-F, Yu S-Q. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology, 2012b;23:495103
   PubMed Web of Science ®Google Scholar
• Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, Unger E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release, 2003;91:167–72
   PubMed Web of Science ®Google Scholar
• Yang X, Hu Z, Chan SY, Goh BC, Duan W, Chan E, Zhou S. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in the rat. J Chromatogr B, 2005;821:221–8
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase i inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res, 1999;5:1189–96
   PubMed Web of Science ®Google Scholar
• Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm, 2004;270:93–107
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release, 2004;96:135–48
   PubMed Web of Science ®Google Scholar
• Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, Martinez A, Gao Y, Lozanguiez Y, Longley C, et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjugate Chem, 2008;19:849–59
   PubMed Web of Science ®Google Scholar